Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by RoyMax123on Nov 12, 2024 1:26pm
21 Views
Post# 36308601

RE:I wonder....

RE:I wonder....No 2 is done, so most likely No 1 will be announced shortly.

francoisl13 wrote: ...if KNE set the expectations to high (again) for Q4...here's what they are targeting for Q4/2024 (from their September presentation):
1. Financing announcement
2. Potential M&A announcement
3. Announce distribution agreements outside of North America - (done for some part of the world)
4.Obtain clearance from Health Canada on revyve Antimicrobial Wound Gel - (didn't see any official announcement)
5.Launch revyve Antimicrobial Wound Gel Spray
6.Commence DispersinB University of Miami Clinical Trial

It is Nov.5th...I wonder if any of the above will happen in Q4 considering that we're basically left with only 5-6 weeks before the Holidays and very little of the above have been confirmed and announced.

I understand that KNE is in a highly supervised and reglemented market but, setting up the expectations and then not meeting them is not doing any good to the company reputation especially with the investment community.

As I said many times, I like this company product lines and the way they are managing it but, not their 'bat average' in regards to meeting expectations they are setting up themself...

GLTA!


<< Previous
Bullboard Posts
Next >>